AAV
Gene Therapy at a Crossroads: Rethinking AAV Amid Industry Resets
Daniel Smith, Ph.D.
Nice Consulting
PAO-05-25-NI-02May 06, 2025
M&A
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Novo Holdings A/S
PR-M04-22-05Apr 07, 2022
COVID-19 Vaccine
Pfizer and BioNTech to Vaccinate Olympic Athletes in Tokyo
Pfizer
PR-M05-21-014May 20, 2021
Emergency Use
Pfizer and BioNtech Receive First U.S. Authorization for Emergency Use of Covid-19 Vaccine in Adolescents
Pfizer
PR-M05-21-007May 11, 2021
COVID-19
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Pfizer
PR-M11-20-007Nov 10, 2020
COVID-19 Vaccine
Pfizer and BioNTech Announce Data from Preclinical Studies of COVID-19 Vaccine Candidate
Pfizer
PR-M09-20-NI-15Sep 11, 2020
Agreement
PPD Signs New Service Agreement with Pfizer
PPD clinical research business of Thermo Fisher Scientific
PR-M08-20-NI-08Aug 04, 2020
COVID-19 Vaccine
Pfizer and BioNTech to Receive $2 Billion from U.S. Government
Pfizer
PR-M07-20-NI-33-1383Jul 23, 2020
COVID-19 Vaccine
Pfizer and BioNTech Report T Cell Response in COVID-19 Vaccine
Pfizer
PR-M07-20-NI-30Jul 21, 2020
COVID-19 Vaccine
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer
PR-M06-20-NI-042Jul 02, 2020
Investment
Pfizer Establishes New Program to Support Continued Biotechnology Innovation
Pfizer
PR-M06-20-NI-001Jun 02, 2020
Medical Professionals Across Merck, Pfizer, and Eli Lilly Volunteer Amid COVID-19 Pandemic
Eli Lilly and Company
PR-M04-20-NI-004 Apr 02, 2020
M&A
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
Mylan
PR-M03-20-NI-041Mar 26, 2020
Vaccine
Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
BioNTech
PR-M03-20-NI-031Mar 20, 2020
Artificial Intelligence
Insilico Enters into Artificial Intelligence Collaboration with Pfizer
Insilico Medicine
PR-M01-20-NI-029Jan 17, 2020
Drug Pricing
Gene Therapy Payment Questions Linger
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M11-19-NI-003Nov 12, 2019
Licensing Agreement
Akcea and Pfizer Inc. Announce Licensing Agreement for Investigative Antisense Therapy Akcea-ANGPTL3-LRX
Pfizer
PR-M10-19-NI-020Oct 11, 2019
Leadership
Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman
Pfizer
PR-M09-19-NI-053Sep 27, 2019
Vaccine
Pfizer Announces Positive Preliminary Results from a 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate for Disease Prevention in Infants
Pfizer
PR-M09-19-NI-028Sep 11, 2019
Investment
The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance
The Pfizer Foundation
PR-M08-19-NI-072Aug 26, 2019